National Guide of Good Clinical Practice for the Diagnosis and Treatment of Lung Cancer

Objectives

Provide a national good clinical practice framework for the diagnosis, staging, treatment and palliation of lung cancer in Serbia, applicable across primary, secondary and tertiary healthcare. The framework aims to embed evidence-based recommendations in routine practice, harmonise clinical decisions, improve healthcare quality and safety, and support subsequent clinical pathways.[1][2][3]It combines international scientific evidence with Serbian healthcare-system and socio-economic conditions to promote clinically advanced but locally applicable care.[4]

• Strengthen prevention by reducing exposure to active and passive tobacco smoke, radon and other occupational or environmental carcinogens, while promoting smoking cessation and healthy lifestyles. Tobacco exposure is identified as the principal risk factor, with more than 85% of lung cancers attributed to active or passive smoking.[5][6]
• Support early recognition and accurate diagnosis through assessment of symptoms, physical condition, imaging, laboratory testing, pathological confirmation and use of the least invasive suitable diagnostic procedure.[7][8][9]
• Stage disease consistently using tumour, node, metastasis classification for non-small-cell lung cancer and limited versus extensive disease classification, alongside tumour, node, metastasis staging where appropriate, for small-cell lung cancer.[10][11][12][13]
• Guide treatment by stage, histology, resectability, mediastinal nodal involvement, molecular characteristics, performance status, comorbidity and patient fitness.[14][15][16]
• Provide multimodality treatment for non-small-cell lung cancer, using surgery for selected early-stage disease, chemoradiotherapy for locally advanced unresectable stage III disease, systemic therapy for advanced disease, and radiotherapy where curative or palliative treatment is appropriate.[17][18][19][20]
• Deliver combined chemotherapy and radiotherapy for limited-stage small-cell lung cancer, generally using cisplatin plus etoposide, and provide platinum-based systemic treatment, supportive care and symptom-directed interventions for extensive-stage disease.[21][22][23]
• Integrate palliative care from diagnosis in advanced disease to control pain, dyspnoea, cough, pleural effusions and other symptoms, support families, and protect quality of life.[23][24][25]

Implementation

Development was led by the Republic Expert Commission for the Development and Implementation of Good Clinical Practice Guidelines within the Ministry of Health of the Republic of Serbia, supported professionally, technically and organisationally by the Serbian Agency for Accreditation of Health Institutions.[1][4]Multidisciplinary national working groups and reviewers developed the guidance through expert knowledge, literature review, analysis of major multicentre studies and consideration of national healthcare circumstances.[4][3][26]The intended delivery model is routine application by healthcare professionals at every level of care; the guidance is described as non-binding for doctors, although wider professional adoption was proposed.[2][3]

• Publish the full guideline and its references through the Accreditation Agency website, with an adapted version intended for publication in the Serbian medical journal Srpski arhiv.[3]
• Use multidisciplinary assessment and pathological confirmation to plan treatment, especially for mediastinal nodal disease, potentially curable metastatic findings and complex stage III non-small-cell lung cancer.[10][27][28]
• Apply structured diagnostic pathways beginning with clinical assessment, chest radiography, laboratory tests and computed tomography of the chest and upper abdomen, followed where indicated by positron emission tomography-computed tomography, magnetic resonance imaging, bone imaging, bronchoscopy, needle biopsy, endobronchial or endoscopic ultrasound, thoracoscopy and surgical staging.[8][29][30][31]
• Use histological samples where possible to distinguish tumour subtypes and support molecular testing, including epidermal growth factor receptor mutation analysis where relevant to treatment selection.[8][32][33]
• Plan radiotherapy with computed tomography-based target delineation, immobilisation, dose-volume assessment of organs at risk and three-dimensional conformal techniques; consider respiratory-motion assessment, four-dimensional computed tomography and positron emission tomography-computed tomography where additional precision is required.[34][35]
• Tailor systemic therapy for advanced non-small-cell lung cancer through platinum-based doublets for patients with good performance status, alternatives where platinum is unsuitable, histology-specific use of pemetrexed, molecularly targeted therapy for appropriately selected patients, and defined maintenance or later-line treatment options.[36][37][38][39]
• Deliver palliative bronchoscopic interventions only where trained staff and interventional-bronchoscopy expertise are available, selecting techniques according to airway obstruction, haemoptysis and institutional capability.[40]
• Monitor clinical care through staging, pathological verification, treatment response, disease progression, performance status, toxicity, symptom relief, quality of life and radiotherapy dose constraints.[35][37][20][41]
• Recognise that no document-wide monitoring schedule, nationally defined implementation indicators, reporting system, audit process, accountability framework, implementation budget or lung-cancer-specific resource allocation is specified in the supplied material.[2][17][19][23]

Monitoring & Evaluation

The guideline provides a national clinical framework for lung-cancer diagnosis and treatment, but it does not establish a document-wide monitoring and evaluation system with defined targets, reporting cycles, audit arrangements, surveillance governance or named accountability bodies.[1][2][3]Its evaluation content is principally clinical: epidemiological burden measures, diagnostic accuracy, staging, treatment response, toxicity, quality of life and outcomes reported from studies.[42][43][44][45]

• Monitor national lung-cancer burden through incidence, mortality, sex-specific trends and international comparisons. Serbia was reported to have approximately 5,200 new bronchial and lung-cancer cases and 4,600 deaths annually; the guideline also reports rising standardised incidence and mortality between 1999 and 2008, particularly among women.[42]
• Assess patient fitness and treatment suitability using Karnofsky or Eastern Cooperative Oncology Group, World Health Organization and Zubrod performance-status scales, alongside quality-of-life and functional assessment.[7][46][43]
• Measure diagnostic quality through pathological confirmation, tumour, node and metastasis classification, imaging performance and procedural accuracy. Computed tomography, positron-emission tomography, endobronchial ultrasound, transthoracic biopsy and mediastinoscopy are accompanied by reported sensitivity, specificity, predictive-value or accuracy measures.[47][29][48][31]
• Confirm positive positron-emission tomography findings cytologically or histologically and use invasive assessment where less invasive mediastinal tests are negative or inconclusive.[14]
• Monitor selected low-risk solitary pulmonary nodules using high-resolution computed tomography every three months during the first year and every six months during the following year.[49]
• Apply radiotherapy quality assurance through computed-tomography-based planning, target and organ-at-risk delineation, respiratory-motion assessment where needed, and dose-volume histogram review. The guidance gives lung-dose constraints, including V20 of approximately 35% to 37% and mean lung dose of 20 to 23 Gy.[34][35]
• Assess systemic-treatment continuation through response, progression, survival, symptom palliation, weight loss, performance status and unacceptable toxicity. In the absence of response, the guidance supports stopping chemotherapy after four cycles and generally limiting cytotoxic doublets to six cycles.[15][39][16]
• Track treatment outcomes in the clinical setting through resection margins, nodal status, response to induction therapy, operability and disease progression.[17][50][51]
• Monitor palliative care through pleural-effusion reaccumulation and drainage volume, pain mechanism and intensity, and the effectiveness and tolerability of analgesic treatment.[24][41]
• Use reported study outcomes as evidence benchmarks, including local control, survival, response rates, brain-metastasis incidence, toxicity and quality of life, rather than as nationally mandated performance indicators.[52][53][40][21][54]

Surveillance is therefore represented mainly by epidemiological data and repeated clinical assessment rather than by a specified national cancer registry or implementation dashboard. The bibliography cites European mortality data and Serbian public-health sources, but does not define operational reporting requirements or accountability mechanisms.[55][56]

Costing & Financing

Financing information is limited. Development of the good clinical practice guideline series was supported by three European Union-funded projects, while the Ministry of Health project “Health System Development of Serbia” was financed through a World Bank credit from 2003 to 2008; additional financing supported preparation of eight guidelines in 2011.[2]No total programme budget, lung-cancer-specific allocation, unit cost, medicine price, reimbursement arrangement, funding gap, resource-mobilisation plan or economic evaluation is specified.[1][2][3]

• Record European Union project support for development of the guideline series, without a stated monetary value.[2]
• Record World Bank credit financing for the “Health System Development of Serbia” project during 2003–2008, without a stated value.[2]
• Record additional financing for a new series of eight guidelines in 2011, without a stated monetary value.[2]
• Recognise that the clinical guidance describes resource-intensive services, including advanced imaging, pathology, surgery, radiotherapy, chemotherapy, molecular testing, bronchoscopy and palliative care, but provides no costing or affordability analysis for their implementation.[8][29][19][40][38][23]
• Note that treatment-centre technical capability is identified as relevant to selecting definitive chemoradiotherapy, but no associated workforce, equipment or capital-resource requirements are quantified.[50]

Clinical outcome percentages, radiation doses and treatment-cycle limits are not financial values and should not be interpreted as budgets or cost estimates.[57][35][58]